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Incidental Thyroid Papillary Microcarcinoma: Survival and Follow-up
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Objectives/Hypothesis: The aim was to study the survival of incidental thyroid papillary microcarcinoma patients treated
with surgery for benign thyroid disease to validate absence of oncological follow-up and reduce unnecessary health expenses.
Study Design: Retrospective cohort study.
Methods: We analyzed patient’s files and interviewed 252 patients by telephone whose cases were submitted to the mul-
tidisciplinary meeting of thyroid pathology in Strasbourg, France, for incidental thyroid papillary microcarcinoma without clini-
cal lymph node involvement, between January 1996 and December 2012.
Results: Thirteen patients (5.8%) died while the data were being collected; however, none of the deaths were due to the
thyroid pathology, and no patients showed signs of relapse of the thyroidectomy or cervical lymph node level.
Conclusions: Our retrospective study shows that patients with incidental localized thyroid papillary microcarcinoma who
underwent surgery without radioactive iodine treatment have an identical survival compared to the general population at the
same age to validate absence of oncological follow-up and reduce unnecessary health expenses.
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INTRODUCTION
Although thyroid cancer is the most common cancer
of the endocrine system, it only represents 1.2% of all
malignant tumors.1 In France, its incidence is low, esti-
mated at about 8,000 new cases per year.2 Thyroid cancer
has an excellent prognosis in its differentiated form, with
a very low mortality rate in France (i.e., 0.3 per 100,000
people per year or just over 400 deaths per year). This
type of cancer is not considered a public health problem
because of its low incidence and favorable prognosis and
low mortality; however, the increase in its incidence is a
medico-economic growth issue.3
The most frequent histological form is papillary car-
cinoma (85%).4 Microcarcinomas are the most frequent
and are defined by a size ≤10 mm without crossing the
gland’s capsule.2 They are mainly an incidental discovery
during the final pathological examination of the parts of
partial or total thyroidectomy for patients operated on for
benign thyroid pathology. During the past 30 years,
incidence of papillary microcarcinoma has increased in
industrialized countries. This evolution is explained by
the increase in their diagnosis, mainly due to more dili-
gent pathological analysis.2,5 Their mortality rate is less
than 1%, which is an excellent prognosis.6
The latest US and French recommendations in the
event of incidental discovery from a partial thyroidectomy
do not recommend radioactive iodine treatment or recur-
rent node dissection for N0 patients (clinically or by ultra-
sound), or completion thyroidectomy. They recommend a
lobo-isthmectomy in cases of preoperative suspicion of
papillary microcarcinoma.7
On the other hand, the modalities of the postopera-
tive follow-up are not standardized and are dependent on
the centers, surgeons, and doctors.8 We carried out a ret-
rospective study from January 1996 to December 2012, in
which a thyroid papillary microcarcinoma was an inciden-
tal discovery, and evaluated the survival of patients oper-
ated on in Alsace, France. Our aim was to study the
survival of these patients to validate the methods of the
multidisciplinary meeting of thyroid pathology reference
center in Alsace, France: the absence of completion thy-
roidectomy, absence of radioactive iodine treatment,
absence of thyroid-stimulating hormone (TSH) suppres-
sion, and absence of oncological follow-up of these
patients considered cured to reduce unnecessary health
expenses (consultations, follow-up, ultrasound).
MATERIALS AND METHODS
All patients’ records presented for thyroid carcinoma during
the multidisciplinary meeting of thyroid pathology at the Paul
Strauss Center, Strasbourg, France, were studied between
January 1996 and December 2012. This reference center is the
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only one in Alsace listing all of the thyroid carcinomas of the
region of Alsace and the east of Moselle, France. During this
period, 1,554 patients with a thyroid carcinoma were presented
for immediate postoperative treatment.
Among the 1,554 patients, 252 were selected because they
had a papillary microcarcinoma incidentally discovered during
pathological examination. These lesions were precisely ≤10 mm,
uni- or multifocal (additional size of ≤10 mm), without crossing
the thyroid capsule, and without cervical lymphadenopathy
detected before or during surgery by clinical examination or cervi-
cal ultrasound (pT1aNx or pT1amNx from the TNM Classification
of Malignant Tumours, 7th Edition). The size reported was deter-
mined with the anatomopathological analysis (largest diameter).
All patients underwent preoperative thyroid and cervical
ultrasound to eliminate cervical nodes. Among all of the patients,
patients with thyroid nodules suspected of malignancy in preopera-
tive treatment with fine-needle aspiration, classified as Bethesda
IV, V, or VI, were excluded. Those with a Bethesda classified I, II,
or III were included. When extemporaneous examination was in
favor of a malignant lesion, the patients were excluded.
The following data were used: patient’s age, date of surgery,
surgeon’s name, date of the multidisciplinary meeting, procedure
performed (lobo-isthmectomy, total thyroidectomy, subtotal thy-
roidectomy), surgical indication, and in particular, toxicity or
pretoxic goiter, number of papillary microcarcinoma, histological
size, reports of consultations, hospitalizations of thyroid surgery
for medium-term surgical outcomes, signs of locoregional or dis-
tant recurrence, death, and cause of death.
A telephone survey was developed and used for these
252 patients. This included information on their survival,
whether there were signs of a locoregional or distant oncological
evolution of their incidental papillary thyroid microcarcinoma,
and surgical outcomes (i.e., dysphonia, hypocalcemia). As well as
the impact of the intervention and levothyroxine supplementa-
tion on daily living. The minimal follow-up was 5 years after the
intervention, allowing us to consider these complications as
definitive and study medium-term surgical outcomes. We inter-
viewed patients on their oncological history in search of an asso-
ciation with other cancers.
The voice was not objectively assessed. Patients were
described as dysphonic when describing a change in their voice com-
pared to the preoperative consultation (modification of the tone or
power of the voice, tiredness of the voice, impossibility or difficulty
to sing). Hypocalcemia was retained for patients taking calcium
supplementation or vitamin D therapy at the time of interview, only
when they had been initiated as a result of the intervention.
Patients were asked about whether or not levothyroxine
was taken, as well as the experience of this daily hormonal sup-
plementation. In the event of a telephone call failure, the general
practitioner was asked the information or helped us contact
patients. Regarding the death of the patients, the information
was given by the family and then confirmed by family doctor,
thus ensuring the absence of a link with the thyroid pathology.
Quantitative variables were described using the usual sta-
tistics of position and dispersion (i.e., mean, median, variance,
minimum, maximum, and quantiles). Qualitative variables were
described using proportions of the modality and cumulative pro-
portions for variables with more than two modalities. All ana-
lyses were carried out in R software version 3.1 (R Foundation
for Statistical Computing, Vienna, Austria).
RESULTS
Between January 1996 and December 2012, 1,554
patients were presented with thyroid carcinoma during
the multidisciplinary meeting of thyroid pathology at the
Paul Strauss Center. Two hundred fifty-two patients were
included, representing 16.2% with a papillary microcarci-
noma of incidental discovery, classified as pT1aNx
(American Joint Committee on Cancer 7th Edition) or
pT1amNx (additional size ≤10 mm) and without cervical
nodes (clinical or ultrasound). The incidence of these
microcarcinomas before 2001 is an average of seven new
cases per year, and after 2001 the incidence is of 18 new
cases per year.
We were unable to reach 27 patients by telephone or
through their general practitioner. Our final study
resulted in 225 patients (Fig. 1). Their medical files did
not contain any arguments in favor of recurrence or
death. The mean age at diagnosis was 65.1 years, with a
standard deviation of 11.8 years (range, 30–95 years;
median age of 66 years). The sex ratio was 0.2 male/
female, with 182 women (80.9%) and 43 men. The mean
lesion size was 4.4 mm, with a standard deviation of
2.5 mm (range, 0.4 mm–10 mm). Multifocality con-
cerned 22 patients, representing 9.8%.
The surgical indications were: 69.3% for euthyroid
heteronodular goitre, 15.1% for toxic heteronodular goi-
tre, 8% for single node, and 7.6% for Graves’ disease.
Among the 225 patients of the cohort, 190 (84.4%)
patients had a total thyroidectomy. Partial surgery was
performed for 35 patients (15.6%): lobo-isthmectomy in
34 patients and one isthmectomy. Completion thyroidec-
tomy for recurrence of goiter at the level of the remaining
lobe involved four of these 35 patients (11.4%), none
because of the cancer lesion originally objectified. None
of these anatomopathology lesions were found to be
malignant.
For 222 patients, the multidisciplinary meeting
recommended no further radioactive iodine treatment.
Fig. 1. Flowchart of the process for selection of the patients ana-
lyzed in the study. [Color figure can be viewed in the online issue,
which is available at www.laryngoscope.com.]
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Only three (1.3%) were postoperatively administered
100 mCi of radioactive iodine in 1996 and 1997 due to a
lesion reaching the upper limit of 10 mm or a doubt on
the thyroid capsule crossing. On the entire body scintigra-
phy following therapy, there was no ganglion metastasis
or distant metastasis found (Table I).
The recommendations of the multidisciplinary meeting
changed in 2001 to total thyroidectomy. Prior to this date,
TSH suppression and regular ultrasound monitoring were
recommended. After that date, the experts concluded that
no TSH suppression and no oncological follow-up were
needed.
In cases of partial surgery, it has always been
advised an annual ultrasound monitoring of the remain-
ing lobe to control for the absence of recurrence (goiter
and macronodule). The time between diagnosis and our
survey was an average of 12 years and 3 months, with a
standard deviation of 4.8 years (range, 5–19 years.
Median = 12 years). While the data were being collected,
13 patients died (5.8%), though none due to their thyroid
pathology. None of the patients required intervention at a
minimum follow-up of 5 years. None manifested disease
or showed signs of relapse at the thyroidectomy or cervi-
cal lymph node level. Among the 212 patients who were
interviewed, 21 (9.9%) reported a voice complaint, with-
out distinction, of lack of voice projection, tiredness dur-
ing the day, a lower or monotonous voice, difficulties
singing. None complained of dyspnea.
Calcium supplementation or vitamin D treatment
was initiated in the immediate aftermath of the operation
and continued for 12 patients (5.7%). For the patients
treated with lobo-isthmectomy, 46.4% required hormonal
supplementation with levothyroxine. Thirty-five out of
197 patients requiring hormone supplementation (17.8%)
and considered this treatment to be a problem in their
daily lives, 20 because of the difficulty in finding the cor-
rect balance, 12 because of a significant weight gain since
the introduction of hormonal supplementation, and five
due to mood changes (Table II).
For the 180 patients who underwent total thyroidec-
tomy, 20.4% were monitored by cervical ultrasound, with
very random follow-up and rhythm, which ranged from
once a year to once every 2 years. There was a monitored
entire-body scintigraphy for 1.9% patients who had no
additional radioactive iodine treatment. A second cancer
was diagnosed for 21 patients (13 breast cancers).
DISCUSSION
Among patients presented during the multidisciplin-
ary meeting for thyroid carcinoma, 16.2% were incidental
papillary microcarcinomas, which are results comparable
to data found in the literature (i.e., 20%).9,10 The inci-
dence of papillary microcarcinomas has almost tripled in
industrialized countries over the past 30 years. This evo-
lution is explained by the growths of instrumental diag-
nosis (e.g., ultrasound, fine-needle aspiration) and the
modernized techniques in sampling, conditioning, and
reading for pathologists.9–11
Our results illustrate this evolution with an average
of seven new cases per year from 1996 to 2000, compared
to 18 new cases per year from 2001 onward. The notion of
overdiagnosis is mention in the literature. It is defined by
establishing a diagnosis of a tumor that, untreated,
will lead to neither symptoms nor death. Vaccarella
et al. estimate that more than 470,000 women and 90,000
men have been overdiagnosed for thyroid cancer during
the last 20 years in a study conducted in 12 industrialized
countries (including France, Italy, South Korea, United
States, and Australia).12
This trend is currently being pointed out by politicians
to reduce healthcare spending (WHO press release
no. 246 of August 18, 2016: “Over-diagnosis is a major driver
of the thyroid cancer epidemic: up to 50%–90% of thyroid
cancers in women in high-income countries), and also by
surgeons and doctors more aware of the risk–benefit bal-
ance of the treatments proposed. The American Thyroid
Association (ATA) recommends no fine-needle aspiration on
nodules ≤10 mm regardless of their ultrasound.7
In our study, we investigated incidental thyroid pap-
illary microcarcinoma with a risk of very low relapse
(ATA 2015 Risk Stratification System With Proposed
TABLE I.
Characteristics of Patients Operated on in Alsace With Incidental
Papillary Microcarcinomas From January 1996 to July 2015.





Average size, mm 4.4
Multifocal, n (%) 22 (9.8)
Surgery indications, n (%)
Euthyroid heteronodular goiter 156 (69.3)
Toxic heteronodular goiter 34 (15.1)
Thyroid nodes 18 (8)
Grave’s disease 17 (7.6)
Surgery, n (%)




Completion thyroidectomy in a second time 4 (11.4)






Total thyroidectomy, n = 180 11 19 180
Partial thyroidectomy, n = 32
No completion
thyroidectomy, n = 28
0 1 13
Completion thyroidectomy
in a second time, n = 4
1 1 4
Data are presented as number of patients.
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Modifications) (i.e., intrathyroid, without locoregional or
distant metastasis, focal or multifocal).6,13,14 Among
them, we focused on those with optimal prognosis, as
defined by Mazzaferri et al.: multifocals with an addi-
tional size of ≤10 mm.15 In the study by Sugitani et al.,16
out of 230 patients with asymptomatic thyroid papillary
microcarcinoma not operated on, 1% developed a locore-
gional evolution over an average follow-up period of
5 years. Our work covered 225 surgically treated patients,
interviewed with an average follow-up of 12 years and
3 months. None reported signs of recurrence at the thy-
roidectomy or cervical lymph node level, and none died
due to their thyroid pathology.
These results are in line with the ATA, which describes
an excellent prognosis of thyroid papillary microcarcinoma,
with a mortality rate of <1%, a locoregional relapse rate of
2% to 6%, and metastasis of 1% to 2%.7 All of these conclu-
sions have been recently illustrated by two Japanese pro-
spective studies,7,16 which concluded that survival between
initial surgery and close surveillance of this type of lesion is
identical. In 1,235 patients, Ito et al.13 observed a minority
of patients (3.5%) who had progression of the disease over a
75-month follow-up period, and no deaths related to the thy-
roid pathology, making surveillance an alternative option
for surgery.
Concerning the surgical attitude, the ATA advocates
a less-invasive attitude by recommending lobectomy
rather than total thyroidectomy, and the absence of radio-
active iodine treatment for the management of thyroid
papillary microcarcinomas of preoperative discovery. For
tumors of perioperative discovery, the attitude should be
the same as if the diagnosis of cancer had been made pre-
operatively.12 The multidisciplinary meeting supports
these recommendations by not proposing total thyroidec-
tomy for partial thyroidectomy, and by never proposing
radioactive iodine treatment since 1997.
Over the years, multiple tumor classification systems
have been developed, always with the aim of predicting
the risk of recurrence and death related to the disease.12
The latest classification in thyroid cancer is the TNM
Classification of Malignant Tumours, Eighth Edition
(2017), classifying papillary carcinomas of <10 mm with
minimal crossing of the thyroid capsule no longer in T3
but in T1a. However, Siddiqui et al. are not the first to
demonstrate an increased risk of lymph node enlarge-
ment in patients with extrathyroid extension of microcar-
cinomas.6,10,17 Thus, particular attention must be paid to
these lesions in the coming years to ensure that these are
lesions with very low risk of recurrence.18 In all cases,
cervical lymph node involvement, unchanged between the
two classifications, seems to be the fundamental indicator
in terms of prognosis, more than the size of the lesion
itself or the minimal extrathyroid involvement.
Dysphonia occurring after thyroid surgery has been
described in 51% to 87% of the patients,19,20 whereas the
recurrent involvement is only objectified in 0.9%21 to 13%
of the cases.22 The causes, in addition to recurrent paraly-
sis, are numerous, some of which may be difficult to objec-
tify and differentiate: adherence of laryngeal and
paralaryngeal muscles, involvement of the external
branch of the upper laryngeal nerve, secondary lesions to
intubation, and postoperative complications of a preoper-
ative pathology.23 These postoperative dysphonias may
be persistent up to 6 months after surgery, and 14% of
patients are impaired.20 These numbers are close to our
results, with 9.9% of our patients reporting a lack of pro-
jection, tiredness of the voice during the day, a lower and
monotonous voice, and difficulty singing.
Calcium supplementation or vitamin D treatment was
reported by 12 patients (5.7%), whereas post-thyroidectomy
definitive hypocalcemia is described in the literature in
0.9%21 to approximately 6% of patients.24 In our study, the
population is predominantly female; our results may have
been increased due to the confusion among telephone inter-
viewees between post-thyroidectomy hypocalcemia and the
prevention of osteoporosis. Furthermore, Conzo et al.21 had
a transitory hypoparathyroidism number of 9.5% of patients
who had thyroid surgery. Perhaps some of our patients had
transitory hypoparathyroidism that required the introduc-
tion of supplementation that was not stopped.
Among the patients who had total thyroidectomy,
6.1% had long-term hypocalcemia and 10.6% had long-
term dysphonia. When the patient underwent a lobo-isth-
mectomy, these numbers were lowered to 0% and 3.6%,
respectively. These results are in line with the experts
seeking to minimize surgical involvement to limit the risk
of postoperative complications. With a rate of multifocal
lesions of only 9.8%, we advocate for the same attitude.
The authors are unanimous that to obtain optimal surgi-
cal results with the least possible morbidity, it is essen-
tial to be a trained, experienced surgeon who is regularly
informed of the innovations and evolution of technical
procedures and their indications.25,26 Of the patients
treated with lobo-isthmectomy, 46.4% required hormonal
supplementation with levothyroxine versus the 20% usu-
ally described.27
Follow-up aims for early detection of persistence or
recurrence of the disease, either in the thyroid or lymph
nodes, to rapidly adopt a therapeutic strategy. This study
proves that for very low-risk cancers, surgery alone cures
them.16 Carcinology follow-up is unnecessary in terms of
patients’ survival and quality of life. Of the patients trea-
ted with total thyroidectomy, 22.2% were overly moni-
tored. Follow-up has a cost. It comes mainly from the lack
of information of general practitioners and patients, wor-
ried about the implications of the word cancer and then
left on their own. Our goal is to remind them to minimize
unnecessary health expenses.
For cancers with good prognosis or proven remission,
there is no evidence that a suppressive dose of LT4 is use-
ful or justified,16 which is why the multidisciplinary meet-
ing does not recommend it. A second cancer was diagnosed
in 21 patients (13 breast cancers). This correlation is
mainly explained by epidemiological data, breast cancer
being the most frequent cancer for women, who are more
represented than men in thyroid pathology.
CONCLUSION
Our study shows that patients with incidental
intrathyroid papillary microcarcinoma treated with partial
or total thyroidectomy without additional treatment by
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iodine-131 have identical survival compared to the general
population at the same age. These data reinforce the cur-
rent recommendations in favor of fewer interventions and
less invasive management. They validate the absence of
oncological follow-up and keep the quality of life of the
patients a priority and limiting unnecessary healthcare
costs.
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